Ould Ouali Cid, Ladjouzi Nadia, Tamas Khidher, Raveloson Hendriniaina, Ben Hassen Jihene, El Omeiri Nesrine, Zouloumis Georges, Al Zoabi Mohamed Moataz, Asadi Muneer, Jhouri Aziza, Schlatter Joël
Department of Post-Acute and Rehabilitation Care, Department of Critical Geriatric Medicine, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Pharmacy, Hospital of Paul Doumer, Assistance Publique des Hôpitaux de Paris (AP-HP), 60140 Labruyère, France.
Geriatrics (Basel). 2022 Feb 21;7(1):22. doi: 10.3390/geriatrics7010022.
The new coronavirus disease 2019 (COVID-19) could be associated with elevated inflammatory cytokine levels, suggesting the involvement of cytokine release syndrome. This syndrome is characterized by release of interleukin 6 correlated with COVID-19 severity and mortality. Targeting IL-6 with Tocilizumab treatment could be a potential therapeutic option for old patients. We report the case of an 88-year-old man with COVID-19 disease who presented at the admission with anemia, fever, oxygen desaturation (92%), and inflammatory syndrome (C-reactive protein (CRP) at 182.5 mg/L; reference range <5.0 mg/L). After remaining CRP level increase (206.6 mg/L), Tocilizumab administration led to rapid clinical outcome and resolution of his inflammatory syndrome. This case report represents a supplementary data confirming the efficacy and safety of Tocilizumab for COVID-19 in elderly patients.
新型冠状病毒肺炎（COVID-19）可能与炎性细胞因子水平升高有关，提示细胞因子释放综合征的参与。该综合征的特征是白细胞介素6的释放与COVID-19的严重程度和死亡率相关。用托珠单抗治疗靶向白细胞介素6可能是老年患者的一种潜在治疗选择。我们报告了一例88岁的COVID-19男性患者，入院时出现贫血、发热、氧饱和度降低（92%）和炎症综合征（C反应蛋白（CRP）为182.5mg/L；参考范围<5.0mg/L）。在CRP水平持续升高（206.6mg/L）后，给予托珠单抗治疗使患者临床症状迅速改善，炎症综合征得以缓解。本病例报告提供了补充数据，证实了托珠单抗治疗老年COVID-19患者的有效性和安全性。
